← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Proneurogen, Inc.
Tucson, AZ
$2,793,562
Total funding
6
Grants
Funding over time
peak $999.4K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,793,562 · 6
By mechanism
R43$2,793,562 · 6
Investigators at Proneurogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia$499,763
R43 · FY2022 · AG
Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias$499,598
R43 · FY2022 · AG
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular$499,545
R43 · FY2023 · AG
Novel formulations of Allopregnanolone to treat Alzheimer's Disease$449,886
R43 · FY2019 · AG
Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment$439,355
R43 · FY2020 · AG
Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)$222,855
R43 · FY2019 · AG
Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)$182,560
R43 · FY2019 · AG